<DOC>
	<DOCNO>NCT00785668</DOCNO>
	<brief_summary>This single centre , single dose pharmacokinetic/safety study male female asthmatic subject . Subjects receive single dose 10 mg AER 001 administer dry powder use handheld device . The goal study understand pharmacokinetics safety AER 001 administer dry powder mild moderate asthmatic .</brief_summary>
	<brief_title>A Phase 1 Safety Pharmacokinetics Study AER 001 Administered Dry Powder Asthmatic Subjects</brief_title>
	<detailed_description>Study Design - Single centre , single dose PK/safety study male female asthmatic subject . - Approximately 10 subject dose . - Treatments administer dry powder inhalation use handheld device - Subjects attend Unit screen eligible return Unit day dose ( Day 1 ) . Subjects require stay overnight Unit discharge Day 2 . - On study Day 1 , subject receive single administration AER 001 . N.B . Screening take place within 28 day prior administration AER 001 . Primary objective : To investigate pharmacokinetics AER 001 administer dry powder mild moderate asthmatic . Secondary objective : To investigate safety AER 001 administer dry powder mild moderate asthmatic .</detailed_description>
	<criteria>Adult male female &gt; 18 year . Subjects female , currently pregnant breast feed use medically acceptable method contraception male , female partner use medically acceptable method contraception . Subjects pre study medical history , physical examination , 12 Lead ECG acceptable investigator . Subjects clinical laboratory test within reference range clinically acceptable investigator . Subjects negative HbsAg , hepatitis C antibody HIV II I test screen . Subjects negative drug abuse screen admission . Subjects negative alcohol admission . Subjects improvement FEV1 &gt; 10 % follow 400 ug salbutamol administration use spacer device . Subjects FEV1 &gt; 70 % predict screen pre dose . Subjects receive steroid treatment prior week . Subjects nonsmoker least 3 month prior screen . Subjects &lt; 10 pack year smoke history . Subjects satisfy Global Initiative Asthma ( GINA , 2002 ) definition asthma treatment asthma . Subjects FEV 1 /FVC ratio &gt; 0.65 screen predose . Subjects stable , adequately treat medical condition may enrol provide Principal Investigator consider study participation place increase risk adverse event . Subjects continue concomitant treatment without change study . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder would preclude participation . Subjects history relevant drug hypersensitivity . Subjects history alcoholism . Subjects history drug abuse . Subjects consume 28 unit ( male ) / 21 unit ( female ) alcohol week . ( unit = 1 glass wine = 1 measure spirit = Â½ pint beer ) Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) Subjects acute respiratory infection influenza time screen and/or admission . Female subject pregnant , breast feeding , use acceptable method contraception . Male subject whoare use acceptable method contraception partner childbearing potential use acceptable method contraception . Subjects use investigational drug /or participate clinical trial within 3 month first dose . Subjects use medication , opinion Investigator affect outcome study . Subjects donate and/or receive blood blood product within previous 3 month prior first dose ( review case case basis ) . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects previously take AER 001 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergy</keyword>
	<keyword>Interleukin-4</keyword>
	<keyword>Interleukin-13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-13</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Aerovance</keyword>
	<keyword>dry powder</keyword>
</DOC>